Myriad Genetics Inc (MYGN)

21.67
NASDAQ : Services
Prev Close 21.50
Day Low/High 21.25 / 21.95
52 Wk Low/High 19.10 / 46.24
Avg Volume 1.73M
Exchange NASDAQ
Shares Outstanding 69.13M
Market Cap 1.49B
EPS 1.80
P/E Ratio 12.57
Div & Yield N.A. (N.A)

Latest News

MYGN: Insiders vs. Shorts

MYGN: Insiders vs. Shorts

The most recent short interest data was recently released for the 07/29/2016 settlement date, and Myriad Genetics, Inc. is one of the most shorted stocks of the Russell 3000, based on 21.79 "days to cover" versus the median component at 6.42.

Bearish Bets: A Defense Firm, an Oil Driller and Other Stocks That Look Good Short

AIR, DO, MLNX, HALL and MYGN were all recently downgraded by TheStreet's Quant Ratings.

Will Myriad Genetics (MYGN) Stock React to Price Target Cut at Jefferies?

Will Myriad Genetics (MYGN) Stock React to Price Target Cut at Jefferies?

Jefferies lowered its price target to $20 on Myriad Genetics (MYGN) stock this morning saying that 'hereditary cancer cracks are emerging.'

Myriad Genetics Has Downside in Its DNA

Myriad Genetics Has Downside in Its DNA

All the long-term indicators are aligned for declines.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AOSL, ARES, BREW, CHTR, FSIC, GBDC, IPAR, LUK, LUNA, NRCIA, ODP, OLED, PIP, STRL, VIPS Downgrades: BCRH, CBNK, DF, HALL, MDVN, MYGN, NMR, NYRT, SGU, TCRD, TEO Initiations: APPF, GLPI, SPNE, TDOC Read on to get TheStreet Quant Ratings' detailed report:

5 Big Stocks to Add to Your Buy List -- Plus 2 to Avoid

5 Big Stocks to Add to Your Buy List -- Plus 2 to Avoid

Here's a technical look at how to trade some of the most active stocks on the market right now.

Why I Feel Bearish About the Market

Why I Feel Bearish About the Market

I'm not inclined to make market calls, but the action on my screen is pushing me to a defensive stance.

Myriad Genetics (MYGN) Stock Tumbles on Q4 Earnings Miss, Guidance

Myriad Genetics (MYGN) Stock Tumbles on Q4 Earnings Miss, Guidance

Following Tuesday's market close, Myriad Genetics (MYGN) reported lower-than-expected earnings for the 2016 fourth quarter and lowered guidance for the year.

Analysts' Actions -- Coach, SunPower, Wayfair, Yelp and More

Analysts' Actions -- Coach, SunPower, Wayfair, Yelp and More

Here are Wednesday's top research calls, including upgrades for Coach and Yelp, and downgrades for SunPower and Wayfair.

Myriad Genetics Signs Definitive Agreement To Acquire Assurex Health

Myriad Genetics Signs Definitive Agreement To Acquire Assurex Health

Allows Entry Into Attractive High-Growth Neuroscience Market

Analysts' Actions -- Dow, Ford, Harley, Target and More

Analysts' Actions -- Dow, Ford, Harley, Target and More

Here are Friday's top research calls, including downgrades for Harley-Davidson and Ford, an upgrade for Dow Chemical and new coverage on Target.

Crescendo Bioscience Announces That New Data On Vectra® DA Will Be Presented At The European League Against Rheumatism 17th Annual Congress

Crescendo Bioscience Announces That New Data On Vectra® DA Will Be Presented At The European League Against Rheumatism 17th Annual Congress

Three Studies Demonstrate the Utility of Vectra DA to Help Predict Treatment Response and Remission in Patients with RA

Myriad MyRisk® Hereditary Cancer Test Demonstrates The Magnitude Of Breast And Ovarian Cancer Risk In Nearly 100,000 Patients

Myriad MyRisk® Hereditary Cancer Test Demonstrates The Magnitude Of Breast And Ovarian Cancer Risk In Nearly 100,000 Patients

New Studies at the 2016 ASCO Annual Meeting Demonstrate a 2- to 40-Fold Increased Risk

Myriad Will Present Three New Hereditary Cancer Studies At The ASCO Annual Meeting

Myriad Will Present Three New Hereditary Cancer Studies At The ASCO Annual Meeting

New Data Highlight the Power of the Myriad myRisk® Hereditary Cancer Test To Identify More Mutation Carriers Without Increased Risk of Distress

Myriad Acquires Sividon Diagnostics

Myriad Acquires Sividon Diagnostics

Strengthens Market Leading Oncology Product Portfolio with Breast Cancer Prognostic Test EndoPredict®

Myriad To Present New Research At The 2016 ASCO Annual Meeting

Myriad To Present New Research At The 2016 ASCO Annual Meeting

Data Demonstrate Expanded Utility of the Myriad myRisk® Hereditary Cancer Test

Myriad To Present Three New Studies At The AUA Annual Meeting

Myriad To Present Three New Studies At The AUA Annual Meeting

New Data Highlight the Power of the Prolaris® Test to Predict 10-Year Oncologic Outcomes in Patients with Low-Risk Localized Prostate Cancer